Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q3 2024 · 10-Q
Revenue$41.69K$41.69K−95.8% vs Q3 2023 Net Income-$4.70M-$4.70MN/M vs Q3 2023 EPS Diluted-$0.55-$0.55N/M vs Q3 2023 Operating Income-$4,681,349N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,641,761N/M Margins · derivedOperating margin-11228.7%−10389.0 pt vs Q3 2023
Net margin-11279.4%−10449.5 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end